Expression and significance of PTEN in canine mammary gland tumours

Research in Veterinary Science

Volumn 85, Issue 2, 2008, Pages 383-388

  Qiu, Changwei ^a,b   Lin, Degui ^a   Wang, Jinqiu ^a   Wang, Lei ^c  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

^b HUAZHONG AGRICULTURAL UNIVERSITY   (China)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Canine mammary gland tumour; Metastasis; PTEN; Real time quantitative PCR

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANIMAL DISEASE; ANIMAL TISSUE; ARTICLE; BENIGN TUMOR; BREAST CANCER; BREAST CARCINOGENESIS; BREAST TUMOR; DIAGNOSTIC VALUE; DOG; FEMALE; LYMPH NODE METASTASIS; NONHUMAN; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH;

ANIMALS; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; PLASMIDS; PTEN PHOSPHOHYDROLASE;

EID: 45049085220     PISSN: 00345288     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rvsc.2007.10.015     Document Type: Article

References (46)

1. Ali I.U., Schrimi L.M., and Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. Journal of the National Cancer Institute 91 (1999) 1922-1932
2. Brodey R.S., Goldschmidt M.A., and Roszel J.R. Canine mammary gland neoplasms. Journal of American Animal Hospital Association 19 (1983) 61-90
3. Brunelle M., Sartin E.A., Wolfe L.G., Sirois J., and Dore M. Cycollxygenase-2 expression in normal and neoplastic canine mammary cell lines. Veterinary Pathology 43 (2006) 656-666
4. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., and Anderson M.J. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 (1999) 857-868
5. Cantley L.C., and Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/Akt pathway. Proceedings of National Academy of Sciences USA 96 (1999) 4240-4245
6. Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., and Reed J.C. Regulation of cell death protease caspase-9 by phosphorylation. Science 282 (1998) 1318-1321
7. Culmsee K., Gruber A.D., Von Samson-Himmelstjerna G., and Nolte I. Quantification of MDR-1 gene in canine tissues by real-time reverse transcription quantitative polymerase chain reaction. Research in Veterinary Science 77 (2004) 223-229
8. Dahia P.L. PTEN, a unique tumour suppressor gene. Endocrine-Related Cancer 7 (2000) 115-129
9. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., and Greenbero M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
10. Depowski P.L., Rosentthal S.I., and Ross J.S. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Modern Pathology 14 (2001) 672-676
11. Di Cristofano A., and Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell 100 (2000) 387-390
12. Garcia J.M., Silva J., Pena C., and Bonilla F. Promoter methylation of the PTEN gene is common molecular change in breast cancer. Genes, Chromosomes and Cancer 41 (2004) 117-124
13. Giulietti A., Overbergh L., Valckx D., and Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 25 (2001) 386-401
14. Gu J., Tamura M., and Yamada K.M. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. Journal of Cell Biology 143 (1998) 1375-1383
15. Huang J., and Kontos C.D. PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. Journal of Biological Chemistry 277 (2002) 10760-10766
16. Kanae Y., Endoh D., Yokota H., Taniyama H., and Hayashi M. Expression of the PTEN tumor suppressor gene in malignant mammary gland tumors of dogs. American Journal of Veterinary Research 67 (2006) 127-133
17. Karin S. Canine mammary gland tumors. Veterinary Clinics Small Animal Practice 33 (2003) 573-596
18. Khan S., Kumagai T., Vora J., Bose N., Sehgal I., Koeffler P.H., and Bose S. PTEN promoter is methylated in a proportion of invasive breast cancers. International Journal of Cancer 112 (2004) 407-410
19. Koenig A., Bianco S.R., Fosmire S., Wojcieszyn J., and Modiano J.F. Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressor in canine melanoma. Veterinary Pathology 39 (2002) 458-482
20. Kondo K., Yao M., Kobayashi K., Ota S., Yoshida M., Kaneko S., and Baba M. PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. International Journal of Cancer 91 (2001) 219-224
21. Koul D., Parthasarathy R., Shen R., Davies M.A., Jasser S.A., Chintala S.K., Rao J.S., and Sun Y. Suppression of matrix metallonproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene 20 (2001) 6669-6678
22. Lee C.H., Kim W.H., Lim J.H., Kang M.S., Kim D.Y., and Kweon O.K. Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors. Journal of Veterinary Science 5 (2004) 63-69
23. Levine R.A., Forest T., and Smith C. Tumor suppressor PTEN is mutated in canine oeteosarcoma cell lines and tumors. Veterinary Pathology 39 (2002) 372-378
24. Maehama T., and Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. Journal of Biological Chemistry 273 (1998) 13375-13378
25. Misdorp W. Canine malignant mammary tumors. Veterinary Pathology 9 (1972) 447-470
26. Misdorp, W., Else, R.W., Hellmen, E., Lipscomb, T.P., 2001. Histological classification of mammary tumors of the dog and the cat. World Health Organization International Histological of Classification of Tumors of Domestic Animals. 2nd Series, vol. VII. Armed Forces Institute of Pathology, American Registry of Pathology, Washington, DC.
27. Munoz J., Lazcoz P., Inda M.N., Nistal M., Pestana A., Encio I.J., and Castresana J.S. Homozygous deletion and expression of PTEN and DMBT1 in human primary neuroblastoma and cell lines. International Journal of Cancer 109 (2004) 673-679
28. Murakami Y., Tateyama S., Rungsipipat A., Uchida K., and Yamaguchi R. Immunohistochemical analysis of cyclin A, cyclin D1 and p53 in mammary tumors, squamous cell carcinomas and basal cell tumors of dogs and cats. Journal of Veterinary Medical Science 62 (2000) 743-750
29. Mutter G.L., Lin M.C., Fitzgerald J.T., Kum J.B., Baak J.P., Lees J.A., and Eng C. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. Journal of the National Cancer Institute 92 (2000) 924-930
30. Nieto A., Pena L., Perez-Alenza M.D., Sanchez M.A., Flores J.M., and Castano M. Immunohistologic detection of estrogen receptor alpha in canine mammary tumors; clinical and pathologic association and prognostic significance. Veterinary Pathology 37 (2000) 239-247
31. Owen L.N. A comparative study of canine and human breast cancer. Investigation in Cell Pathology 2 (1979) 257-275
32. Priester W.A. Occurrence of mammary neoplasms in bitches in relation to breed, age, tumor type, and geographical region from which reported. Journal of Small Animal Practice 20 (1979) 1-11
33. Salvesen H.B., Macdonald N., Ryan A., Jacobs I.G., Lynch E.D., Akslen L.A., and Das S. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. International Journal of Cancer 91 (2001) 22-26
34. Schneider R., Dorn C.R., and Taylor D.O. Factors influencing canine mammary cancer development and postsurgical survival. Journal of the National Cancer Institute 43 (1969) 1249-1261
35. Schwartzbauer G., and Robbins J. The tumor suppressor gene PTEN can regulate cardiac hypertrophy and survival. Journal of Biological Chemistry 276 (2001) 35786-35793
36. Stambolic V., Tsano M.S., and Macpherson D. High incidence of breast and endometrial neoplasia resembling human cowden syndrome in PTEN +/- mice. Cancer Research 60 (2000) 3605-3611
37. Steck P.A., Pershouse M.A., Jasser S.A., and Hadi A. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genetics 15 (1997) 356-362
38. Tamura M., Gu J., Tran H., and Yamada K.M. PTEN gene and integrin signaling in cancer. Journal of the National Cancer Institute 91 (1999) 1820-1828
39. Teng D.H., and Hu R. MMAC1/PTEN mutations in primary tumour specimens and tumour cell lines. Cancer Research 57 (1997) 5221-5225
40. Tsttsui S., Inoue H., and Yasuda K. Inactivation of PTEN is associated with a low p27kipl protein expression in breast carcinoma. Cancer 104 (2005) 2048-2053
41. Waite K.A., and Eng C. Protein PTEN: form and function. American Journal of Human Genetics 70 (2002) 829-844
42. Wang T., and Brown M.J. mRNA quantification by real time TaqMan polymerase chain reaction: validation and comparison with RNase protection. Analytical Biochemistry 269 (1999) 198-201
43. Wang D.S., Rieger-Christ K., Latini J.M., Moinzadeh A., Stoffel J., Pezza J.A., Saini K., Librtino J.A., and Summerhayes I.C. Molecular analysis of PTEN in primary bladder carcinoma. International Journal of Cancer 88 (2000) 620-625
44. Weng L., Brown J., and Eng C. PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Human Molecular Genetics 10 (2001) 237-242
45. Yuan X.J., and Wang Y.E. PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 21 (2002) 319-327
46. Zhou X.P., Gimm O., and Hampel H. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. American Journal of Pathology 157 (2000) 1123-1128